176 related articles for article (PubMed ID: 37829303)
1. Effectiveness and safety of pelareorep plus chemotherapy versus chemotherapy alone for advanced solid tumors: a meta-analysis.
Xie R; Huang H; Chen T; Huang X; Chen C
Front Pharmacol; 2023; 14():1228225. PubMed ID: 37829303
[No Abstract] [Full Text] [Related]
2. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of zolbetuximab for first-line treatment of advanced Claudin 18. 2-positive gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized controlled trials.
Liang Z; Liu L; Li W; Lai H; Li L; Wu J; Zhang H; Fang C
Front Oncol; 2023; 13():1258347. PubMed ID: 37886169
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis.
Liu X; Zhang J; Feng K; Wang S; Chen L; Niu S; Lu Q; Fang Y
Front Pharmacol; 2022; 13():1023533. PubMed ID: 36452227
[No Abstract] [Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis.
Zhang T; Li W; Diwu D; Chen L; Chen X; Wang H
Front Immunol; 2023; 14():1197044. PubMed ID: 37435087
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis.
Chen W; Miao J; Wang Y; Xing W; Xu X; Wu R
Front Pharmacol; 2023; 14():1212313. PubMed ID: 37484016
[No Abstract] [Full Text] [Related]
10. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma.
Blank O; von Tresckow B; Monsef I; Specht L; Engert A; Skoetz N
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007110. PubMed ID: 28447341
[TBL] [Abstract][Full Text] [Related]
11. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials.
Li X; Yan S; Yang J; Wang Y; Lv C; Li S; Zhao J; Yang Y; Zhuo M; Wu N
Front Oncol; 2020; 10():574752. PubMed ID: 33585195
[TBL] [Abstract][Full Text] [Related]
13. Oral versus intravenous fluoropyrimidines for colorectal cancer.
Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
[TBL] [Abstract][Full Text] [Related]
14. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.
Shao T; Zhao M; Liang L; Tang W
Front Immunol; 2022; 13():948597. PubMed ID: 36389713
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of anti-PD-1/PD-L1 in treatment of glioma: a single-arm meta-analysis.
Zeng YF; Wei XY; Guo QH; Chen SY; Deng S; Liu ZZ; Gong ZC; Zeng WJ
Front Immunol; 2023; 14():1168244. PubMed ID: 37122727
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis.
Liu Y; Huang Y; Li J; Wan S; Jiang N; Yang J; Chiampanichayakul S; Tima S; Anuchapreeda S; Wu J
Front Pharmacol; 2022; 13():1010626. PubMed ID: 36438821
[No Abstract] [Full Text] [Related]
17. A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial.
Jonker DJ; Tang PA; Kennecke H; Welch SA; Cripps MC; Asmis T; Chalchal H; Tomiak A; Lim H; Ko YJ; Chen EX; Alcindor T; Goffin JR; Korpanty GJ; Feilotter H; Tsao MS; Theis A; Tu D; Seymour L
Clin Colorectal Cancer; 2018 Sep; 17(3):231-239.e7. PubMed ID: 29653857
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Long Y; Song X; Guan Y; Lan R; Huang Z; Li S; Zhang L
J Gastroenterol Hepatol; 2023 Apr; 38(4):486-495. PubMed ID: 36516040
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of taxanes combined with chemotherapy drugs in advanced triple negative breast cancer: A meta-analysis of 26 randomized controlled trials.
Huang Q; Mei Z; Han X
Front Oncol; 2022; 12():972767. PubMed ID: 36119468
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy and radiotherapy for advanced pancreatic cancer.
Chin V; Nagrial A; Sjoquist K; O'Connor CA; Chantrill L; Biankin AV; Scholten RJ; Yip D
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD011044. PubMed ID: 29557103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]